Table 3 Multivariate analysis of locoregional recurrence-free survival (LRFS), relapse-free survival (RFS), and overall survival (OS) in patients with (i) T2-3N0M0 and (ii) T2-3N1-2M0 stage disease.
From: Benefit of Adjuvant Chemoradiotherapy in Resected Gallbladder Carcinoma
Factor | LRFS | RFS | OS | ||||
|---|---|---|---|---|---|---|---|
HR (95% CI) | * p | HR (95% CI) | * p | HR (95% CI) | * p | ||
(i) T2-3N0M0 | |||||||
T classification | T2 | 1.000 | 1.000 | — | |||
T3 | 13.341 (4.098–43.433) | 0.001 | 8.351 (3.204–21.763) | <0.001 | — | — | |
Vascular invasion | No | — | — | 1.000 | |||
Yes | — | — | — | — | 5.703 (1.964–16.561) | 0.001 | |
Perineural invasion | No | — | — | 1.000 | |||
Yes | — | — | — | — | 3.398 (1.308–8.825) | 0.012 | |
(ii) T2-3N1-2M0 | |||||||
N classification | N1 | 1.000 | 1.000 | 1.000 | |||
N2 | 3.232 (1.591–6.566) | 0.001 | 2.621 (1.388–4.948) | 0.003 | 2.232 (1.218–4.091) | 0.009 | |
Postop CA 19-9 level | ≤37 | 1.000 | 1.000 | 1.000 | |||
(U/mL) | >37 | 4.167 (1.929–9.001) | 0.001 | 4.776 (2.366–9.641) | <0.001 | 2.248 (1.215–4.160) | 0.016 |
Vascular invasion | No | — | 1.000 | 1.000 | |||
Yes | — | — | 3.258 (1.384–7.668) | 0.007 | 2.953 (1.620–5.383) | <0.001 | |
Lymphatic invasion | No | 1.000 | — | — | |||
Yes | 5.819 (1.801–18.798) | 0.003 | — | — | — | — | |
Adjuvant Therapy | No-AT | 1.000 | 1.000 | 1.000 | |||
CTx | 0.360 (0.170–0.760) | 0.007 | 0.409 (0.203–0.826) | 0.013 | 0.328 (0.165–0.651) | 0.001 | |
CRT | 0.081 (0.029–0.228) | <0.001 | 0.247 (0.123–0.497) | <0.001 | 0.130 (0.060–0.282) | <0.001 | |
